3D Printed Drugs Market to Reach US$ 57.03 million by 2027 at 9.1% CAGR: The Insight Partners
Zip dose segment to witness significant growth in the global 3D printed drugs market during the forecast period
NEW YORK, UNITED STATES, March 9, 2023 /EINPresswire.com/ -- According to a new market research study titled “3D Printed Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Dosage Forms and Technology,” the global 3D printed drugs market is expected to reach US$ 57.03 Mn in 2027 from US$ 28.52 Mn in 2019. The market is estimated to grow at a CAGR of 9.1% during 2020–2027. The report provides trends prevailing in the global 3D printed drugs market, and the driving and restraining factors pertaining to the market growth.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00010199/
The increasing adoption of personalized medicines and rising awareness regarding 3D printed drugs are the factor driving the growth of the 3D printed market. As per a study published by PMC, personalized medicines accounted for only 5% of the new FDA approved molecular entities in 2005, whereas, in 2016, they accounted for more than 25%.
Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to function as personalized medicines. Moreover, biopharmaceutical companies have nearly doubled their R&D investments in personalized drugs over the past five years, and they are further likely to increase their investment by 33% in the next five years. Biopharmaceutical researchers also predict a 69% hike in the number of personalized medicines in the next five years.
The global 3D printed drugs market, based on technology, is segmented into inkjet printing, direct write, zip dose, thermal inkjet printing, fused deposition modeling, powder bed printing, stereolithography, semi solid extrusion. In 2019, the zip dose segment accounted for the largest share of the market. The segment is expected to grow register the highest CAGR in the market during the forecast period. The increasing adoption of zip dose technology for 3D drug printing is likely to drive the growth of zip dose segment during 2020-2027.
Speak to Analyst @ https://www.theinsightpartners.com/speak-to-analyst/TIPRE00010199
Leading companies operating in the 3D printed drugs market are Aprecia Pharmaceuticals, LLC, FabRx Ltd, Cycle Pharmaceuticals, GlaxoSmithKline PLC., AstraZeneca, Tvasta, and Merck KGGA, among others.
The segmentation of the 3D printed drugs market, as mentioned in the report, has been provided below:
3D printed drugs Market – By Dosage Form
• Tablets
• Capsules
• Multi Drug Implant
• Nanoparticles
• Solutions
• Others Dosage Forms
3D printed drugs Market – By Technology
• Inkjet Printing
• Direct Write
• Zip Dose
• Thermal Inkjet Printing
• Fused Deposition Modeling
• Powder Bed Printing
• Stereolithography (SLA)
• Semi Solid Extrusion (SSE)
Get a Full Report Copy @ https://www.theinsightpartners.com/buy/TIPRE00010199/?utm_source=EINPressWire&utm_medium=10379
About The Insight Partners
The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Healthcare, Media, and Telecommunication.
Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.
Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, products, applications, end users etc., which helps our clients to gain a deeper analytical understanding of various research topics.
Contact Us
If you have any queries about this report or would like further information, please contact us:
Sameer Joshi
The Insight Partners
+91 9666111581
email us here
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
